A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non–small-cell lung cancer (AK104-202 study)

Author:

Zhao Yuanyuan,Ma Yuxiang,Fan Yun,Zhou Jianya,Yang Nong,Yu Qitao,Zhuang Wu,Song Weifeng,Wang Zhongmin Maxwell,Li Baiyong,Xia Yu,Zhao Hongyun,Zhang Li

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference31 articles.

1. Cancer treatment and survivorship statistics, 2022;Miller;CA A Cancer J. Clin.,2022

2. Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China;Gou;Lung Cancer (Auckl),2014

3. NCCN clinical practice guidelines in oncology: non-small cell lung cancer, Version 1.2023;Ettinger;J. Nat. Comprehen. Cancer Network: JNCCN,2022

4. Randomized phase III trial of docetaxel vs vinorelbine or ifosfamide in patients with advancednon-small-cell lung cancer previously treated with platinum-containingchemotherapy;Fossella;J. Clin. Oncol.,2000

5. Docetaxel (Taxotere)shows survival and quality-of-life benefits in the second-line treatment of non-small-celllung cancer: a review of two phase III trials;Shepherd;Semin. Oncol.,2001

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

全球学者库

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2023 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3